

**To:** 5.1.2e 5.1.2e 5.1.2e @rivm.nl  
**From:** 5.1.2e 5.1.2e  
**Sent:** Thur 1/21/2021 4:20:44 PM  
**Subject:** RE: Doorst: Next delivery Moderna vaccine Netherlands  
**Received:** Thur 1/21/2021 4:20:44 PM

Dus eigenlijk zijn ze een week later?!

Geef jij door of Movianto in het weekend ontvangt?

En bespreek jij dit ook met 5.1.2e 5.1.2e 5.1.2e , zodat hij weet waar hij rekening mee moet houden?

Groet,  
5.1.2e

---

**Van:** 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>  
**Verzonden:** donderdag 21 januari 2021 16:46  
**Aan:** 5.1.2e 5.1.2e < 5.1.2e @minvws.nl>  
**Onderwerp:** Doorst: Next delivery Moderna vaccine Netherlands

Hallo 5.1.2e ,  
Ter info,  
Mvrgr  
5.1.2e

---

**Van:** Moderna Vaccine Information < 5.1.5 @moderatx.com>  
**Datum:** 21 januari 2021 om 11:34:19 AST  
**Aan:** 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>, 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>, 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>  
**CC:** 5.1.2e < 5.1.2e @moderatx.com>  
**Onderwerp:** Next delivery Moderna vaccine Netherlands

Dear 5.1.2e ,

We are pleased to share with you the details regarding your next delivery of COVID-19 Vaccine Moderna, in-line with the Estimated Delivery Schedule from January 12th, which has been distributed earlier by the European Commission.

We are happy to confirm that the amount of the next shipment will be as earlier estimated. In the case of Netherlands it will be 5.1.2b Shipping Cases containing 5.1.2b doses.

Please note that for operational reasons, the second wave of deliveries to EU Member States will begin on Friday, January 29th, and will continue over the weekend. The scheduled arrival date and time of the vaccine at your warehouse in Netherlands is: Saturday, January 30th, PM.

Please reply to this email before Monday, January 25th, 12 noon, either agreeing to the proposed delivery schedule or telling us that your receiving warehouse has difficulties in accepting deliveries over the weekend. In the latter case, we would reschedule and deliver the vaccine at the beginning of the following week.

Best regards,  
5.1.2e 5.1.2e , Pharm.D for the Moderna Vaccine Information Team  
5.1.2e Moderna COVID-19 Vaccine - International  
5.1.5 @moderatx.com

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

[www.rivm.nl](http://www.rivm.nl) De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

[www.rivm.nl/en](http://www.rivm.nl/en) Committed to *health and sustainability*